References
- National Cancer Institute. NIH. CAR T cells: engineering patients’ immune cells to treat their cancers. Available from: https://www.cancer.gov/about-cance HYPERLINK "https://www.cancer.gov/about-cancer/treatment/research/car-t-cells"r/treatment/research/car-t-cells. 2022.
- Zhang X, Zhu L, Zhang H, et al. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153. doi:10.3389/fimmu.2022.927153
- Staudt RE, Carlson RD, Snook AE. Targeting gastrointestinal cancers with chimeric antigen receptor (CAR)-T cell therapy. Cancer Biol Ther. 2022;23(1):127–133. doi:10.1080/15384047.2022.2033057
- U.S. Food & Drug Administration. Approved cellular and gene therapy products. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products.
- U.S. Food & Drug Administration L information. KYMRIAH® (tisagenlecleucel) suspension for intravenous infusion. Available from: https://www.fda.gov/media/107296/download.
- U.S. Food & Drug Administration L information. YESCARTA® (axicabtagene ciloleucel) suspension for intravenous infusion. Available from: https://www.fda.gov/files/vaccines%2C%20blood%20 HYPERLINK "https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert-YESCARTA.pdf"& HYPERLINK "https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/Package-Insert-YESCARTA.pdf"%20biologics/published/Package-Insert-YESCARTA.pdf.
- U.S. Food & Drug Administration L information. BREYANZI® (lisocabtagene maraleucel) suspension for intravenous infusion. Available from: https://www.fda.gov/media/145711/download.
- U.S. Food & Drug Administration L. TECARTUS® (brexucabtagene autoleucel) suspension for intravenous infusion. Available from: https://www.fda.gov/media/140409/download.
- U.S. Food & Drug Administration L information. ABECMA® (idecabtagene vicleucel), suspension for intravenous infusion. Available from: https://www.fda.gov/media/147055/down HYPERLINK "https://www.fda.gov/media/147055/download"load.
- U.S. Food & Drug Administration L information. CARVYKTITM(ciltacabtagene autoleucel) suspension for intravenous infusion. Available from: https://www.fda.gov/media/1 HYPERLINK "https://www.fda.gov/media/156560/download"56560/download.
- Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69. doi:10.1038/s41408-021-00459-7
- Cai C, Tang D, Han Y, et al. A comprehensive analysis of the fatal toxic effects associated with CD19 CAR-T cell therapy. Aging (Albany NY). 2020;12(18):18741–18753. doi:10.18632/aging.104058
- Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638. doi:10.1016/j.bbmt.2018.12.758
- Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as Second-Line therapy for large B-Cell lymphoma. N Engl J Med. 2022;386(7):640–654. doi:10.1056/NEJMoa2116133
- Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502. doi:10.1016/S0140-6736(21)01222-8
- Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–324. doi:10.1016/S0140-6736(21)00933-8
- Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. doi:10.1056/NEJMoa2024850
- Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294–2308. doi:10.1016/S0140-6736(22)00662-6
- Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2019;380(1):45–56. doi:10.1056/NEJMoa1804980
- Wudhikarn K, Pennisi M, Garcia-Recio M, et al. DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. Blood Adv. 2020;4(13):3024–3033. doi:10.1182/bloodadvances.2020001972
- Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-Refractory diffuse large B-Cell lymphoma and indolent B-Cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–549. doi:10.1200/JCO.2014.56.2025
- Jacobson CA, Locke FL, Ma L, et al. Real-World evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transplant Cell Ther. 2022;28(9):581.e1-581–e8. doi:10.1016/j.jtct.2022.05.026
- Wang L, Hong R, Zhou L, et al. New-Onset severe cytopenia after CAR-T cell therapy: analysis of 76 patients with relapsed or refractory acute lymphoblastic leukemia. Front Oncol. 2021;11:702644. doi:10.3389/fonc.2021.702644
- Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. doi:10.1056/NEJMoa1709866
- Wallet F, Sesques P, Devic P, et al. CAR-T cell: toxicities issues: mechanisms and clinical management. Bull Cancer. 2021;108(10S):S117–S127. doi:10.1016/j.bulcan.2021.05.003
- Sharma N, Reagan PM, Liesveld JL. Cytopenia after CAR-T cell therapy—a brief review of a complex problem. Cancers (Basel). 2022;14(6):1501. doi:10.3390/cancers14061501
- Sun Z, Liu M. Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma. Cytotherapy. 2022;24(9):940–953. doi:10.1016/j.jcyt.2022.03.009
- Schaefer A, Huang Y, Kittai A, et al. Cytopenias after CD19 chimeric antigen receptor T-Cells (CAR-T) therapy for diffuse large B-Cell lymphomas or transformed follicular lymphoma: a single institution experience. Cancer Manag Res. 2021;13:8901–8906. volumedoi:10.2147/CMAR.S321202
- Thakkar A, Cui Z, Peeke SZ, et al. Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting. Stem Cell Investig. 2021;8:18–18. doi:10.21037/sci-2021-008
- Schuster SJ, Tam CS, Borchmann P, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(10):1403–1415. doi:10.1016/S1470-2045(21)00375-2
- Iglesias-Lopez C, Agustí A, Vallano A, et al. Current landscape of clinical development and approval of advanced therapies. Mol Ther Methods Clin Dev. 2021;23:606–618. doi:10.1016/j.omtm.2021.11.003
- U.S. Food & Drug Administration. Cellular & Gene Therapy Products. [cited 2022 Sep 10]. Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products. 2022.
- FDA Adverse Events Reporting System (FAERS). [cited 2021 Feb 1]. Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest HYPERLINK "https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files"-quarterly-data-files.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). MedDRA® the Medical Dictionary for Regulatory Activities. Available from: https://www.meddra.org/.
- FDA. DA Adverse Event Reporting System (FAERS) Public Dashboard. [cited 2021 Sep 21] Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard.
- MedDRA. Introductory guide. Available from: https://www.meddra. org/sites/default/files/guidance/file/smq_intguide_19_0_english.pdf. 2016).
- MedDRA®. Introductory Guide for Standardised MedDRA Queries (SMQs) Version 20.1, September 2017, Accessible at https://admin.meddra.org/sites/default/files/guidance/file/smq_intguide_20_1_english.pdf
- Screening for adverse reactions in EudraVigilance. Europe: European Medicines Agency. December 19th, 2016. Accessible at https://www.ema.europa.eu/en/documents/other/screening-adverse-reactions-eudravigilance_en.pdf
- Maciá-Martínez M-A, de Abajo FJ, Roberts G, et al. An empirical approach to explore the relationship between measures of disproportionate reporting and relative risks from analytical studies. Drug Saf. 2016;39(1):29–43. doi:10.1007/s40264-015-0351-3
- Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519–523. doi:10.1002/pds.1001
- Laetsch TW, Maude SL, Rives S, et al. Three-Year update of tisagenlecleucel in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41(9):1664-1669. doi:10.1200/JCO.22.00642.
- Chhabra P, Chen X, Weiss SR. Adverse event reporting patterns of newly approved drugs in the USA in 2006: an analysis of FDA adverse event reporting system data. Drug Saf. 2013;36(11):1117–1123. doi:10.1007/s40264-013-0115-x
- Weber J. Epidemiology of adverse reactions to nonsteroidal antiinflammatory drugs. Adv Inflamm Res.
- Hoffman KB, Dimbil M, Erdman CB, et al. The Weber effect and the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010. Drug Saf. 2014;37(4):283–294. doi:10.1007/s40264-014-0150-2.
- Cordeiro A, Bezerra ED, Hirayama AV, et al. Late events after treatment with CD19-Targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant. 2020;26(1):26–33. doi:10.1016/j.bbmt.2019.08.003
- Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019;54(10):1643–1650. doi:10.1038/s41409-019-0487-3
- Rejeski K, Perez A, Iacoboni G, et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. J Immunother Cancer. 2022;10(5):e004475. doi:10.1136/jitc-2021-004475
- Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;138(24):2499–2513. doi:10.1182/blood.2020010543
- Bonaldo, Giulia, Montanaro, Nicola, Motola, Domenico, et al. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice. Eur J Clin Pharmacol, 8 2021; 77: 1225–1234. doi:10.1007/s00228-021-03106-z
- Fusaroli M, Isgrò V, Cutroneo PM, et al. Post-Marketing surveillance of CAR-T-Cell therapies: analysis of the FDA adverse event reporting system (FAERS) database. Drug Saf. 2022;45(8):891–908. doi:10.1007/s40264-022-01194-z
- Guha A, Addison D, Jain P, et al. Cardiovascular events associated with chimeric antigen receptor T cell therapy: cross-Sectional FDA adverse events reporting system analysis. Biol Blood Marrow Transplant. 2020;26(12):2211–2216. doi:10.1016/j.bbmt.2020.08.036
- Edwards BJ, Laumann AE, Nardone B, et al. Advancing pharmacovigilance through academic–legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis—a research on adverse drug events and reports (RADAR) report. Br J Radiol. 2014;87(1042):20140307. doi:10.1259/bjr.20140307